Credit Suisse’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-145,746
| Closed | -$159K | – | 3110 |
|
|
2023
Q3 | $159K | Sell |
145,746
-5,694
| -4% | -$9.99K | ﹤0.01% | 3062 |
|
|
2023
Q2 | $347K | Buy |
151,440
+88,055
| +139% | +$234K | ﹤0.01% | 2957 |
|
|
2023
Q1 | $154K | Buy |
63,385
+20
| +0% | +$46 | ﹤0.01% | 3161 |
|
|
2022
Q4 | $121K | Buy |
63,365
+23,882
| +60% | +$50.8K | ﹤0.01% | 3298 |
|
|
2022
Q3 | $95K | Buy |
39,483
+508
| +1% | +$1.41K | ﹤0.01% | 3440 |
|
|
2022
Q2 | $72K | Sell |
38,975
-4,175
| -10% | -$7.96K | ﹤0.01% | 3584 |
|
|
2022
Q1 | $90K | Buy |
43,150
+406
| +0.9% | +$1.13K | ﹤0.01% | 3483 |
|
|
2021
Q4 | $168K | Sell |
42,744
-2,264
| -5% | -$11K | ﹤0.01% | 4317 |
|
|
2021
Q3 | $216K | Buy |
45,008
+13,446
| +43% | +$55.2K | ﹤0.01% | 4205 |
|
|
2021
Q2 | $144K | Buy |
31,562
+20,526
| +186% | +$98.9K | ﹤0.01% | 4337 |
|
|
2021
Q1 | $65K | Buy |
+11,036
| New | +$76.4K | ﹤0.01% | 4218 |
|
|
2020
Q3 | – | Sell |
-212,017
| Closed | -$423K | – | 4083 |
|
|
2020
Q2 | $423K | Buy |
212,017
+157,616
| +290% | +$309K | ﹤0.01% | 3414 |
|
|
2020
Q1 | $105K | Buy |
54,401
+22,199
| +69% | +$66.1K | ﹤0.01% | 3808 |
|
|
2019
Q4 | $134K | Buy |
32,202
+5,853
| +22% | +$22.5K | ﹤0.01% | 4048 |
|
|
2019
Q3 | $80K | Sell |
26,349
-940
| -3% | -$2.91K | ﹤0.01% | 3986 |
|
|
2019
Q2 | $171K | Sell |
27,289
-2,510
| -8% | -$15K | ﹤0.01% | 3878 |
|
|
2019
Q1 | $166K | Sell |
29,799
-3,733
| -11% | -$22.7K | ﹤0.01% | 3795 |
|
|
2018
Q4 | $223K | Sell |
33,532
-26,945
| -45% | -$218K | ﹤0.01% | 3634 |
|
|
2018
Q3 | $645K | Sell |
60,477
-65,086
| -52% | -$746K | ﹤0.01% | 3154 |
|
|
2018
Q2 | $1.51M | Buy |
125,563
+76,354
| +155% | +$781K | ﹤0.01% | 2701 |
|
|
2018
Q1 | $421K | Sell |
49,209
-1,265
| -3% | -$11.7K | ﹤0.01% | 3443 |
|
|
2017
Q4 | $498K | Sell |
50,474
-14,486
| -22% | -$151K | ﹤0.01% | 3437 |
|
|
2017
Q3 | $798K | Sell |
64,960
-2,527
| -4% | -$37.3K | ﹤0.01% | 3256 |
|
|
2017
Q2 | $1.11M | Sell |
67,487
-25,061
| -27% | -$388K | ﹤0.01% | 2630 |
|
|
2017
Q1 | $1.33M | Buy |
92,548
+19,978
| +28% | +$296K | ﹤0.01% | 2651 |
|
|
2016
Q4 | $1M | Buy |
72,570
+10,106
| +16% | +$162K | ﹤0.01% | 3021 |
|
|
2016
Q3 | $1.13M | Buy |
62,464
+1,638
| +3% | +$26.4K | ﹤0.01% | 2851 |
|
|
2016
Q2 | $873K | Sell |
60,826
-47,152
| -44% | -$640K | ﹤0.01% | 3049 |
|
|
2016
Q1 | $1.29M | Buy |
107,978
+78,416
| +265% | +$822K | ﹤0.01% | 2534 |
|
|
2015
Q4 | $393K | Sell |
29,562
-423
| -1% | -$5.2K | ﹤0.01% | 3537 |
|
|
2015
Q3 | $322K | Sell |
29,985
-92,095
| -75% | -$1.01M | ﹤0.01% | 3678 |
|
|
2015
Q2 | $983K | Buy |
122,080
+42,860
| +54% | +$315K | ﹤0.01% | 3200 |
|
|
2015
Q1 | $524K | Buy |
79,220
+25,854
| +48% | +$177K | ﹤0.01% | 3516 |
|
|
2014
Q4 | $340K | Buy |
53,366
+34,460
| +182% | +$278K | ﹤0.01% | 3973 |
|
|
2014
Q3 | $187K | Sell |
18,906
-12,256
| -39% | -$131K | ﹤0.01% | 4157 |
|
|
2014
Q2 | $350K | Sell |
31,162
-4,977
| -14% | -$53.5K | ﹤0.01% | 4019 |
|
|
2014
Q1 | $437K | Buy |
36,139
+8,402
| +30% | +$107K | ﹤0.01% | 3812 |
|
|
2013
Q4 | $350K | Sell |
27,737
-16,751
| -38% | -$267K | ﹤0.01% | 3980 |
|
|
2013
Q3 | $741K | Buy |
44,488
+6,644
| +18% | +$111K | ﹤0.01% | 3195 |
|
|
2013
Q2 | $575K | Buy |
+37,844
| New | +$575K | ﹤0.01% | 3204 |
|
Other funds holding LXRX
AG
BI
NMC
Credit Suisse's LXRX Position: Q4 2023 in Review
Credit Suisse sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2023, closing a stake of 145,746 shares — an estimated $159K sold.
Credit Suisse first reported a position in LXRX in Q2 2013 and held it in 40 quarters. The position peaked at $1.51M in Q2 2018. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2023.
- Credit Suisse reported no remaining Lexicon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
- Credit Suisse sold 145,746 Lexicon Pharmaceuticals shares in Q4 2023, an estimated $159K.
- Credit Suisse first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 40 quarters.
- Credit Suisse's Lexicon Pharmaceuticals position peaked at $1.51M in Q2 2018.
- 106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2023.
Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.